GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (NAS:ASND) » Definitions » Cyclically Adjusted Price-to-FCF

Ascendis Pharma A/S (Ascendis Pharma A/S) Cyclically Adjusted Price-to-FCF : (As of Jun. 07, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF Chart

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ascendis Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF falls into.



Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Ascendis Pharma A/S's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ascendis Pharma A/S's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.945/118.4000*118.4000
=-1.945

Current CPI (Mar. 2024) = 118.4000.

Ascendis Pharma A/S Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.631 99.700 -0.749
201409 -0.262 99.700 -0.311
201412 -0.560 99.400 -0.667
201503 -0.321 100.200 -0.379
201506 -0.675 100.300 -0.797
201509 -0.572 100.200 -0.676
201512 -0.448 99.800 -0.531
201603 -0.666 100.200 -0.787
201606 -0.583 100.600 -0.686
201609 -0.713 100.200 -0.843
201612 -0.575 100.300 -0.679
201703 -0.713 101.200 -0.834
201706 -0.834 101.200 -0.976
201709 -0.947 101.800 -1.101
201712 -0.781 101.300 -0.913
201803 -1.174 101.700 -1.367
201806 -0.573 102.300 -0.663
201809 -1.324 102.400 -1.531
201812 -0.990 102.100 -1.148
201903 -1.650 102.900 -1.899
201906 -0.149 102.900 -0.171
201909 -1.416 102.900 -1.629
201912 -1.170 102.900 -1.346
202003 -1.679 103.300 -1.924
202006 -1.437 103.200 -1.649
202009 -1.410 103.500 -1.613
202012 -2.172 103.400 -2.487
202103 -1.908 104.300 -2.166
202106 -2.658 105.000 -2.997
202109 -2.343 105.800 -2.622
202112 -2.547 106.600 -2.829
202203 -2.614 109.900 -2.816
202206 -2.427 113.600 -2.530
202209 -1.809 116.400 -1.840
202212 -2.755 115.900 -2.814
202303 -2.827 117.300 -2.854
202306 -2.960 116.400 -3.011
202309 -2.384 117.400 -2.404
202312 -0.818 116.700 -0.830
202403 -1.945 118.400 -1.945

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma A/S  (NAS:ASND) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma A/S (Ascendis Pharma A/S) Business Description

Industry
Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.